Evidence map›Paper›PMID 31626803›Full record

ArticleJournal of molecular biology2019

Paratope Duality and Gullying are Among the Atypical Recognition Mechanisms Used by a Trio of Nanobodies to Differentiate Ebolavirus Nucleoproteins.

Laura Jo Sherwood, Alexander Bryan Taylor, Peter John Hart, Andrew Hayhurst

Open access · hybridAbstract read
In one paragraph

Article in Journal of molecular biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Laura Jo SherwoodDisease Intervention and Prevention, Texas Biomedical Research Institute, San Antonio, TX, 78227, USA.
Alexander Bryan TaylorX-ray Crystallography Core Laboratory, Institutional Research Cores and Department of Biochemistry and Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229, USA.
Peter John HartX-ray Crystallography Core Laboratory, Institutional Research Cores and Department of Biochemistry and Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229, USA; Department of Veterans Affairs, South Texas Veterans Health Care System, San Antonio, TX, 78229, USA.
Andrew HayhurstDisease Intervention and Prevention, Texas Biomedical Research Institute, San Antonio, TX, 78227, USA. Electronic address: http://ahayhurst@TxBiomed.org.
Texas Biomedical Research Institute · USSouth Texas Veterans Health Care System · USThe University of Texas Health Science Center at San Antonio · US

Funding

TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Robin Jean Leach · 1991 to 2026
$59.1M
Overall EvaluationP41GM103403 · NIGMS · CORNELL UNIVERSITY · PI EALICK, STEVEN E · 2012 to 2017
$14.3M
Mechanism and Evolution of Filoviral Monoclonal Affinity Reagent Sandwich AssaysR01AI112851 · NIAID · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI HAYHURST, ANDREW · 2015 to 2019
$2.4M
Pixel Array Detector for X-ray CrystallographyS10RR029205 · NCRR · CORNELL UNIVERSITY · PI EALICK, STEVEN E · 2010 to 2010
$1.8M
Rapid Ligand Pairing Strategy to Simplify Diagnostic Immunoassay AssemblyR21AI105568 · NIAID · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI HAYHURST, ANDREW · 2013 to 2014
$503k
EXTRAMURAL RESEARCH FACILITIES CONSTRUCTIONC06RR012087 · NCRR · SOUTHWEST FOUNDATION FOR BIOMEDICAL RES · PI VANDEBERG, JOHN L · 1996 to 1996
–
NCI NIH HHS P30 CA054174NCRR NIH HHS C06 RR012087NCRR NIH HHS S10 RR029205NIAID NIH HHS R01 AI112851NIAID NIH HHS R21 AI105568NIGMS NIH HHS P41 GM103403
6 · The paper itself

Abstract

We had previously shown that three anti-Marburg virus nanobodies (VHH or single-domain antibody [sdAb]) targeted a cryptotope within an alpha-helical assembly at the nucleoprotein (NP) C-terminus that was conserved through half a century of viral evolution. Here, we wished to determine whether an anti-Ebola virus sdAb, that was cross-reactive within the Ebolavirus genus, recognized a similar structural feature upstream of the ebolavirus NP C-terminus. In addition, we sought to determine whether the specificities of a less cross-reactive anti-Zaire ebolavirus sdAb and a totally specific anti-Sudan ebolavirus sdAb were the result of exclusion from this region. Binding and X-ray crystallographic studies revealed that the primary determinant of cross-reactivity did indeed appear to be a preference for the helical feature. Specificity, in the case of the Zaire ebolavirus-specific sdAb, arose from the footprint shifting away from the helices to engage more variable residues. While both sdAbs used CDRs, they also had atypical side-on approaches, with framework 2 helping to accommodate parts of the epitope in sizeable paratope gullies. The Sudan ebolavirus-specific sdAb was more remarkable and appeared to bind two C-terminal domains simultaneously via nonoverlapping epitopes-"paratope duality." One mode involved paratope gullying, whereas the other involved only CDRs, with CDR3 restructuring to wedge in between opposing walls of an interdomain crevice. The varied routes used by sdAbs to engage antigens discovered here deepen our appreciation of the small scaffold's architectural versatility and also reveal lucrative opportunities within the ebolavirus NP C-termini that might be leveraged for diagnostics and novel therapeutic targeting.

Indexed as

EbolavirusAmino Acid SequenceAntibodies, ViralAntigens, ViralEpitopesHemorrhagic Fever, EbolaHumansModels, MolecularNucleoproteinsProtein BindingProtein ConformationProtein Interaction Domains and MotifsSingle-Domain AntibodiesAntibodies, ViralAntigens, ViralEpitopesNucleoproteinsSingle-Domain AntibodiesAntibody–antigen recognitionFilovirusNanobodyRestructuringSudan ebolavirus

Identifiers

PMID31626803
PMCPMC6990103
OpenAlexW2981241870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.